Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)-Reference-Cited by-同舟云学术

Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

Published:2021-10 Issue: Volume:160 Page:17-27
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tufman Amanda,Neumann Jens,Manapov Farkhad,Sellmer Laura,Jung Andreas,Kauffmann-Guerrero Diego,Kahnert Kathrin,Mertsch Pontus,Borgmeier Astrid,Semrau Sabine,Rittmeyer Achim,Ulm Bernhard,Ulm Kurt,Flentje Michael,Fietkau Rainer,Huber Rudolf Maria

Funder

AstraZeneca

Deutsche Zentrum für Lungenforschung

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.-C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeño, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D.R. Spigel, C. Wadsworth, G. Melillo, M. Taboada, P.A. Dennis, M. Özgüroğlu, Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N. Engl. J. Med. 379 (2018) 2342–2350. DOI:10.1056/nejmoa1809697.

2. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer;Kim;Br. J. Cancer.,2019

3. GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

4. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014;Salgado;Ann. Oncol.,2015

5. J.N. Kather, M. Suarez-Carmona, P. Charoentong, C.A. Weis, D. Hirsch, P. Bankhead, M. Horning, D. Ferber, I. Kel, E. Herpel, S. Schott, I. Zörnig, J. Utikal, A. Marx, T. Gaiser, H. Brenner, J. Chang-Claude, M. Hoffmeister, D. Jäger, N. Halama, Topography of cancer-associated immune cells in human solid tumors, Elife. 7 (2018). DOI:10.7554/eLife.36967.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial tertiary lymphoid structures imply response to anti‐PD‐1 plus anlotinib in advanced non‐small cell lung cancer;Immunology;2024-07-30

2. Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis;Oncology Letters;2024-04-03

3. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy;Biomedicines;2024-03-19

4. A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-12

5. Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression;Current Oncology;2023-08-08